Remibrutinib results in significant improvement in patients still symptomatic after second-generation H1-antihistamine treatment.

Discover 8 ways mast cell activation syndrome causes widespread symptoms from digestive issues to brain fog, often mistaken ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study presented at the ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

Xyzal (levocetirizine) and Zyrtec (cetirizine) are over-the-counter (OTC) allergy medications. Learn about their key ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...

Allergic inflammation plays a big role in allergy reactions and contributes to the itching and chewing commonly seen with ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...